Together Pharma Ltd (TLV: TGTR)
Israel
· Delayed Price · Currency is ILS · Price in ILA370.40
-5.50 (-1.46%)
Oct 15, 2024, 5:24 PM IDT
Together Pharma Income Statement
Financials in millions ILS. Fiscal year is January - December.
Millions ILS. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 95.89 | 91.01 | 31.23 | 12.03 | 11.22 | - | Upgrade
|
| Revenue Growth (YoY) | 43.32% | 191.42% | 159.67% | 7.15% | - | - | Upgrade
|
| Cost of Revenue | 59.21 | 56.38 | 37.12 | 14.2 | -17.06 | 1.42 | Upgrade
|
| Gross Profit | 36.68 | 34.62 | -5.89 | -2.17 | 28.29 | -1.42 | Upgrade
|
| Selling, General & Admin | 13 | 12.53 | 11.61 | 9.55 | 11.29 | 13.76 | Upgrade
|
| Other Operating Expenses | - | - | 2.27 | -1.71 | 0.37 | 0.2 | Upgrade
|
| Operating Expenses | 13 | 12.53 | 13.88 | 9.28 | 11.66 | 13.96 | Upgrade
|
| Operating Income | 23.68 | 22.09 | -19.77 | -11.46 | 16.63 | -15.38 | Upgrade
|
| Interest Expense | -18.06 | -18.78 | -17.02 | -14.8 | -11.85 | -6.76 | Upgrade
|
| Interest & Investment Income | 2.73 | - | - | 10.88 | 8.89 | 6 | Upgrade
|
| Earnings From Equity Investments | -0.06 | -0.25 | -0 | - | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | 0.54 | 0.54 | 1.76 | -0.41 | -1.44 | -0.35 | Upgrade
|
| Other Non Operating Income (Expenses) | -2.06 | -2.06 | -1.3 | 0.01 | 1.94 | -0.17 | Upgrade
|
| EBT Excluding Unusual Items | 6.77 | 1.54 | -36.33 | -15.78 | 14.16 | -16.66 | Upgrade
|
| Pretax Income | 6.77 | 1.54 | -36.33 | -15.12 | 14.16 | -16.66 | Upgrade
|
| Income Tax Expense | 6.71 | 4.07 | -0.85 | - | -1.31 | - | Upgrade
|
| Earnings From Continuing Operations | 0.06 | -2.53 | -35.48 | -15.12 | 15.47 | -16.66 | Upgrade
|
| Net Income to Company | 0.06 | -2.53 | -35.48 | -15.12 | 15.47 | -16.66 | Upgrade
|
| Minority Interest in Earnings | -2.62 | -1.78 | 1.96 | 1.34 | -8.32 | 1.39 | Upgrade
|
| Net Income | -2.56 | -4.32 | -33.52 | -13.78 | 7.15 | -15.28 | Upgrade
|
| Net Income to Common | -2.56 | -4.32 | -33.52 | -13.78 | 7.15 | -15.28 | Upgrade
|
| Shares Outstanding (Basic) | 10 | 9 | 8 | 7 | 6 | 5 | Upgrade
|
| Shares Outstanding (Diluted) | 10 | 9 | 8 | 7 | 6 | 5 | Upgrade
|
| Shares Change (YoY) | 14.48% | 7.81% | 18.96% | 18.76% | 14.93% | 20.35% | Upgrade
|
| EPS (Basic) | -0.26 | -0.49 | -4.15 | -2.05 | 1.27 | -3.04 | Upgrade
|
| EPS (Diluted) | -0.26 | -0.49 | -4.18 | -2.23 | 1.22 | -3.51 | Upgrade
|
| Free Cash Flow | 10.82 | 13.97 | -14.07 | -20.17 | -23.46 | -14.89 | Upgrade
|
| Free Cash Flow Per Share | 1.09 | 1.59 | -1.73 | -2.94 | -4.07 | -2.97 | Upgrade
|
| Gross Margin | 38.25% | 38.04% | -18.85% | -18.07% | 252.03% | - | Upgrade
|
| Operating Margin | 24.69% | 24.28% | -63.31% | -95.27% | 148.18% | - | Upgrade
|
| Profit Margin | -2.67% | -4.74% | -107.35% | -114.55% | 63.73% | - | Upgrade
|
| Free Cash Flow Margin | 11.29% | 15.35% | -45.04% | -167.75% | -208.99% | - | Upgrade
|
| EBITDA | 27.61 | 27.62 | -14.37 | -6.14 | 20.56 | -13.96 | Upgrade
|
| EBITDA Margin | 28.79% | 30.35% | -46.01% | -51.04% | 183.15% | - | Upgrade
|
| D&A For EBITDA | 3.93 | 5.52 | 5.4 | 5.32 | 3.93 | 1.42 | Upgrade
|
| EBIT | 23.68 | 22.09 | -19.77 | -11.46 | 16.63 | -15.38 | Upgrade
|
| EBIT Margin | 24.69% | 24.28% | -63.31% | -95.27% | 148.18% | - | Upgrade
|
| Effective Tax Rate | 99.10% | 264.65% | - | - | - | - | Upgrade
|
| Advertising Expenses | - | 0.57 | 0.83 | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.